Boehringer submits Pradaxa antidote app; Sanofi's Lantus follow-up nears EMA approval;

> Boehringer Ingelheim has submitted an FDA application for its Pradaxa antidote. Release | More

> The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended Sanofi's ($SNY) Lantus follow-up, Toujeo, for European approval. Report

> India's Natco Pharma is challenging the patent on Gilead's Sovaldi despite its licensing agreement to make and sell cheap versions of the drug. More (sub. req.)

> AstraZeneca ($AZN) has completed its deal for Actavis' ($ACT) North American respiratory portfolio. Brief

And Finally... Millennials aren't big on big purchases--even cars and houses--but they do like to spend money on health and fitness gadgets. Infographic

Suggested Articles

Cardiac risks associated with roxadustat are comparable to placebo in nondialysis patients and to Amgen's standard, Epogen, in those on dialysis.

Pfizer and Merck KGaA's immuno-oncology agent Bavencio failed another gastric cancer study, this time as a maintenance treatment after chemotherapy.

A jury ordered Biogen to pay nearly $6 million to a former sales manager who reported a colleague's misconduct and got fired a few months later.